J 2023

Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice

SCHMID, Anna Marlene, Agnieszka RAZIM, Magdalena WYSMOLEK, Daniela KEREKES, Melissa HAUNSTETTER et. al.

Základní údaje

Originální název

Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice

Autoři

SCHMID, Anna Marlene, Agnieszka RAZIM, Magdalena WYSMOLEK, Daniela KEREKES, Melissa HAUNSTETTER, Paul KOHL, Georgii BRAZHNIKOV, Nora GEISSLER, Michael THALER, Eliška KRČMÁŘOVÁ, Martin ŠINDELÁŘ (203 Česká republika, domácí), Tamara WEINMAYER, Jiří HRDÝ, Katy SCHMIDT, Peter NEJSUM, Bradley WHITEHEAD, Johan PALMFELDT, Stefan SCHILD, Aleksandra INIC-KANADA, Ursula WIEDERMANN a Irma SCHABUSSOVA (garant)

Vydání

Cell Communication and Signaling, BMC, 2023, 1478-811X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 8.400 v roce 2022

Kód RIV

RIV/00216224:14310/23:00133086

Organizační jednotka

Přírodovědecká fakulta

UT WoS

001095697400002

Klíčová slova anglicky

Allergic airway inflammation; Extracellular vesicles; Outer membrane vesicles; Microbiota and innate immunity; Nasal route of administration

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 18. 1. 2024 14:28, Mgr. Marie Šípková, DiS.

Anotace

V originále

Background E. coli O83 (Colinfant Newborn) is a Gram-negative (G-) probiotic bacterium used in the clinic. When administered orally, it reduces allergic sensitisation but not allergic asthma. Intranasal administration offers a non-invasive and convenient delivery method. This route bypasses the gastrointestinal tract and provides direct access to the airways, which are the target of asthma prevention. G- bacteria such as E. coli O83 release outer membrane vesicles (OMVs) to communicate with the environment. Here we investigate whether intranasally administered E. coli O83 OMVs (EcO83-OMVs) can reduce allergic airway inflammation in mice. Methods EcO83-OMVs were isolated by ultracentrifugation and characterised their number, morphology (shape and size), composition (proteins and lipopolysaccharide; LPS), recognition by innate receptors (using transfected HEK293 cells) and immunomodulatory potential (in naive splenocytes and bone marrow-derived dendritic cells; BMDCs). Their allergy-preventive effect was investigated in a mouse model of ovalbumin-induced allergic airway inflammation. Results EcO83-OMVs are spherical nanoparticles with a size of about 110 nm. They contain LPS and protein cargo. We identified a total of 1120 proteins, 136 of which were enriched in OMVs compared to parent bacteria. Proteins from the flagellum dominated. OMVs activated the pattern recognition receptors TLR2/4/5 as well as NOD1 and NOD2. EcO83-OMVs induced the production of pro- and anti-inflammatory cytokines in splenocytes and BMDCs. Intranasal administration of EcO83-OMVs inhibited airway hyperresponsiveness, and decreased airway eosinophilia, Th2 cytokine production and mucus secretion. Conclusions We demonstrate for the first time that intranasally administered OMVs from probiotic G- bacteria have an anti-allergic effect. Our study highlights the advantages of OMVs as a safe platform for the prophylactic treatment of allergy.